Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus

被引:30
作者
Serban, M
Tanaseanu, C
Kosaka, T
Vidulescu, C
Stoian, I
Marta, DS
Tanaseanu, S
Moldoveanu, E
机构
[1] Victor Babes Natl Inst Pathol, Ultrastruct Pathol Dept, Bucharest 76201, Romania
[2] Carol Davila Univ Med & Pharm, Fac Med, Dept Pathophysiol, Bucharest, Romania
[3] Carol Davila Univ Med & Pharm, Fac Med, Dept Internal Med, St Pantelimon Emergency Hosp, Bucharest, Romania
[4] Carol Davila Univ Med & Pharm, Fac Med, Dept Cellular & Mol Med, Bucharest, Romania
[5] Carol Davila Univ Med & Pharm, Fac Med, Dept Biochem, Bucharest, Romania
[6] Carol Davila Univ Med & Pharm, Fac Med, Dept Rheumatol, Colentina Hosp, Bucharest, Romania
[7] Nesco Co, Azwell Inc, R&D Div, Diagnost Res & Dev Dept, Osaka, Japan
关键词
platelet-activating factor acetylhydrolase; non-insulin-dependent diabetes mellitus; endothelial cell dysfunction;
D O I
10.1111/j.1582-4934.2002.tb00462.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: Non-insulin dependent diabetes mellitus (NIDDM) represents an independent risk factor for cardiovascular diseases (CVD), being characterized by a continuous low-grade inflammation and endothelial activation state. Plasma platelet - activating factor - acetylhydrolases (PAF-AHs) are a subgroup of Ca2+-independent phospholipase A(2) family (also known as lipoprotein-associated phospholipases A(2)) that hydrolyze and inactivate the lipid mediator platelet-activating factor (PAF) and/or oxidized phospholipids. This enzyme is considered to play an important role in inflammatory diseases and atherosclerosis. The present study aims to investigate the relations between the levels of PAF-AH activity and LDL-cholesterol / HDL-cholesterol (LDL-ch / HDL-ch) ratio in NIDDM patients as compared to controls. Methods: serum PAF-AH activity was measured in 50 patients with dyslipidemia, in 50 NIDDM patients and in 50 controls (normal lipid and glucose levels). Total cholesterol, LDL-ch, HDL-ch, triglyceride and blood glucose were determined in all subjects. Results: All NIDDM patients display hiperlipidemia, with increased LDL-ch and triglyceride levels. There is a significant correlation between LDL-ch levels (especially LDL-ch / HDL-ch ratio) and PAF-AH activity in dyslipidemic and NIDDM patients. Conclusion: Diabetic and dyslipidemic patients have an increased plasma PAF-AH activity correlated with their LDL-ch levels and mainly with LDL-ch / HDL-ch ratio. Plasma PAF-AH high levels appear to be important as a risk marker for endothelial dysfunction in patients with NIDDM.
引用
收藏
页码:643 / 647
页数:5
相关论文
共 20 条
[1]   Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins [J].
Abuja, PM ;
Albertini, R .
CLINICA CHIMICA ACTA, 2001, 306 (1-2) :1-17
[2]   Platelet-activating factor acetylhydrolase [J].
Arai, H .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2002, 68-9 :83-94
[3]   Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma [J].
Asano, K ;
Okamoto, S ;
Fukunaga, K ;
Shiomi, T ;
Mori, T ;
Iwata, M ;
Ikeda, Y ;
Yamaguchi, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 261 (02) :511-514
[4]   Up-regulation of endothelial nitric-oxide synthase promoter by the phosphatidylinositol 3-kinase γ/Janus kinase 2/MEK-1-dependent pathway [J].
Cieslik, K ;
Abrams, CS ;
Wu, KK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (02) :1211-1219
[5]  
Cockerill GW, 2001, CIRCULATION, V103, P108
[6]   PURIFICATION AND CHARACTERIZATION OF PLATELET-ACTIVATING-FACTOR ACETYLHYDROLASE-II FROM BOVINE LIVER CYTOSOL [J].
HATTORI, K ;
HATTORI, M ;
ADACHI, H ;
TSUJIMOTO, M ;
ARAI, H ;
INOUE, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (38) :22308-22313
[7]  
Henry RR, 2001, CLIN DIABETES, V19, P113, DOI DOI 10.2337/DIACLIN.19.3.113
[8]   Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer [J].
Katso, R ;
Okkenhaug, K ;
Ahmadi, K ;
White, S ;
Timms, J ;
Waterfield, MD .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 2001, 17 :615-675
[9]   Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity [J].
Kosaka, T ;
Yamaguchi, M ;
Soda, Y ;
Kishimoto, T ;
Tago, A ;
Toyosato, M ;
Mizuno, K .
CLINICA CHIMICA ACTA, 2000, 296 (1-2) :151-161
[10]   Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese [J].
Kosaka, T ;
Yamaguchi, M ;
Miyanaga, K ;
Mizuno, K .
CLINICA CHIMICA ACTA, 2001, 312 (1-2) :179-183